Using ctDNA to Determine Therapies for Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.
Eligibility criteria
Qualifiers
Age ≥ 18 years at the time of screening
Written informed consent obtained from the subject prior to performing any protocol-related procedures
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Weight ≥ 35 kg
Disqualifiers
Participants that should receive adjuvant chemotherapy per standard of care (resected N1 or N2 disease, primary tumour >=4 cm).
Receipt of any conventional or investigational anticancer therapy within 21 days or radiotherapy within 14 days prior to the scheduled first dose of study treatment;
Prior receipt of any immune-mediated anti-cancer therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies including nivolumab and agents targeting CD73, CD39, or adenosine receptors;
Incomplete surgical resection;
Trial design
Treatments tested in this trial
- Nivolumab
- Pemetrexed
- Gemcitabine
- Cisplatin
- Carboplatin
- ctDNA blood test
Treatment groups
66 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Health Network, Toronto
Lead sponsor
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov